1. Home
  2. KROS vs SMBK Comparison

KROS vs SMBK Comparison

Compare KROS & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KROS
  • SMBK
  • Stock Information
  • Founded
  • KROS 2015
  • SMBK N/A
  • Country
  • KROS United States
  • SMBK United States
  • Employees
  • KROS N/A
  • SMBK N/A
  • Industry
  • KROS Biotechnology: Pharmaceutical Preparations
  • SMBK Major Banks
  • Sector
  • KROS Health Care
  • SMBK Finance
  • Exchange
  • KROS Nasdaq
  • SMBK Nasdaq
  • Market Cap
  • KROS 558.9M
  • SMBK 553.9M
  • IPO Year
  • KROS 2020
  • SMBK N/A
  • Fundamental
  • Price
  • KROS $13.45
  • SMBK $36.08
  • Analyst Decision
  • KROS Buy
  • SMBK Buy
  • Analyst Count
  • KROS 13
  • SMBK 5
  • Target Price
  • KROS $20.63
  • SMBK $34.40
  • AVG Volume (30 Days)
  • KROS 603.2K
  • SMBK 69.7K
  • Earning Date
  • KROS 08-06-2025
  • SMBK 07-21-2025
  • Dividend Yield
  • KROS N/A
  • SMBK 0.89%
  • EPS Growth
  • KROS N/A
  • SMBK 44.84
  • EPS
  • KROS 0.11
  • SMBK 2.26
  • Revenue
  • KROS $214,713,000.00
  • SMBK $171,664,000.00
  • Revenue This Year
  • KROS $5,006.76
  • SMBK $20.95
  • Revenue Next Year
  • KROS N/A
  • SMBK $9.48
  • P/E Ratio
  • KROS $123.44
  • SMBK $15.96
  • Revenue Growth
  • KROS 91657.70
  • SMBK 16.34
  • 52 Week Low
  • KROS $9.12
  • SMBK $23.09
  • 52 Week High
  • KROS $72.37
  • SMBK $37.72
  • Technical
  • Relative Strength Index (RSI)
  • KROS 43.42
  • SMBK 79.16
  • Support Level
  • KROS $13.24
  • SMBK $33.63
  • Resistance Level
  • KROS $13.77
  • SMBK $33.23
  • Average True Range (ATR)
  • KROS 0.38
  • SMBK 0.73
  • MACD
  • KROS -0.04
  • SMBK 0.37
  • Stochastic Oscillator
  • KROS 28.00
  • SMBK 98.09

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

About SMBK SmartFinancial Inc.

SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.

Share on Social Networks: